Sophie Adriana Josepha Maria Rovers

Ms. Sophie Adriana Josepha Maria Rovers

University of Antwerp, Antwerp, Flanders, Belgium
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
Sophie Adriana Josepha Maria RoversSophie Adriana Josepha Maria Rovers
Sophie Adriana Josepha Maria Rovers
AJAnnelies Janssens
Annelies Janssens
JRJo Raskin
Jo Raskin
Patrick PauwelsPatrick Pauwels
Patrick Pauwels
JMJan P. van Meerbeeck
Jan P. van Meerbeeck
EMElly Marcq
Elly Marcq
Malignant pleural mesothelioma (MPM) is a fatal cancer type that affects the membranes lining the lungs, and is causally associated with asbestos exposure. Until recently, the first-line treatment consisted of a combination of chemotherapeutics that only had a limited impact on survival, and had not been improved in decades. With the recent approval of combined immune checkpoint inhibition for MPM, promising new immunotherapeutic strategies are now emerging for this disease. In this review, we describe the current preclinical and clinical evidence of various immune checkpoint inhibitors in MPM. We will consider the advantages of combined immune checkpoint blockade in comparison with single agent checkpoint inhibitor drugs. Furthermore, recent evidence suggests a role for T cell immunoglobulin and ITIM domain (TIGIT), an inhibitory immunoreceptor, as a novel target for immunotherapy. As this novel immune checkpoint remains largely unexplored in mesothelioma, we will discuss the potential of TIGIT blockade as an alternative therapeutic approach for MPM. This review will emphasize the necessity for new and improved treatments for MPM, while highlighting the recent advances and future perspectives of combined immune checkpoint blockade, particularly aimed at PD-L1 and TIGIT.

18 March 2025 in Cells
Verified
Journal Article
Open access
PDF file
Ruben VerloyRuben Verloy
Ruben Verloy
Angela Privat MaldonadoAngela Privat Maldonado
Angela Privat Maldonado
JAJonas Van Audenaerde
Jonas Van Audenaerde
Sophie Adriana Josepha Maria RoversSophie Adriana Josepha Maria Rovers
Sophie Adriana Josepha Maria Rovers
HZHannah Zaryouh
Hannah Zaryouh
Annemie  BogaertsAnnemie Bogaerts
Annemie Bogaerts
Pancreatic ductal adenocarcinoma (PDAC) presents significant treatment challenges due to its desmoplastic reaction, which impedes therapeutic effectiveness, highlighting the need for advanced vitro models to better mimic the complex tumor environment. The current three-dimensional co-culture models of fibroblasts and endothelial cells are lacking, which presents a challenge for performing more comprehensive in vitro research. Our study developed triple co-culture spheroid models using MiaPaCa-2 and BxPC-3 cancer cell lines, with RLT-PSC and hPSC21 pancreatic stellate cell lines and the endothelial cell line HMEC-1. These models were assessed through growth assays, multicolor flow cytometry to optimize cell ratios, cell viability assays to evaluate drug responses, and a tube formation assay with a spheroid-conditioned medium to examine angiogenesis. Our triple co-culture spheroids effectively replicate the PDAC microenvironment, showing significant variations in drug responses influenced by cellular composition, density, and spatial arrangement. The tube formation assay showcased the potential of our models to quantitatively assess a treatment-induced angiogenic response. These cost-effective triple-co-culture in vitro spheroid models provide vital insights into the PDAC microenvironment, significantly improving the quality of the in vitro evaluation of treatment responses.

29 May 2025 in OncoImmunology
Verified
Journal Article
Open access
Sophie Adriana Josepha Maria RoversSophie Adriana Josepha Maria Rovers
Sophie Adriana Josepha Maria Rovers
JAJonas Van Audenaerde
Jonas Van Audenaerde
RVRuben Verloy
Ruben Verloy
JWJorrit De Waele
Jorrit De Waele
LBLouize Brants
Louize Brants
ESEvelien Smits
Evelien Smits
Pleural mesothelioma (PM) is an aggressive cancer caused by asbestos exposure, with limited treatment options and poor prognosis, highlighting the need for more effective therapies. Combining immune checkpoint blockade with anti-angiogenic therapy has shown potential in other cancers. Our study investigated the combined inhibition of PD-L1 and VEGFR2 in a mouse model of PM. Using C57BL/6 mice with subcutaneous AE17 mesothelioma tumors, we assessed the effects of anti-PD-L1 therapy with induction, concomitant, or consolidation anti-VEGFR2 treatment. Mice received intraperitoneal doses every three days for three treatments. Tumor growth, survival, tumor-infiltrating immune cells and intra-tumoral vasculature were analyzed. Results demonstrated that combining anti-PD-L1 with induction or concomitant anti-VEGFR2 significantly delayed tumor growth, improved survival, and promoted vascular maturation. Flow cytometry suggested T cell exhaustion in monotherapy groups, while no significant changes were seen with concomitant treatment. Depleting CD4+ T cells reversed the positive effects of concomitant treatment. These findings suggest that dual inhibition of PD-L1 and VEGFR2 is a promising therapeutic approach for PM, with CD4+ T cells playing a critical role in the immune response. This dual targeting of immune checkpoints and angiogenesis offers a potential new avenue for improving outcomes in PM treatment and warrants further clinical exploration.

28 May 2025 in Methods and Protocols
Verified
Journal Article
Open access
PDF file
Sophie Adriana Josepha Maria RoversSophie Adriana Josepha Maria Rovers
Sophie Adriana Josepha Maria Rovers
PFPooyeh Farahmand
Pooyeh Farahmand
DLDana Yinfay Liu
Dana Yinfay Liu
LBLouize Brants
Louize Brants
CHChristophe Hermans
Christophe Hermans
ESEvelien Smits
Evelien Smits
The development of standardised, reproducible preclinical models is essential for advancing pleural mesothelioma (PM) research. Here, we present a simple and reliable minimally invasive transthoracic intrapleural injection technique that could improve the efficiency of orthotopic PM model generation. By incorporating a simple needle sleeve to control the injection depth, this method eliminates the need for surgery or general anaesthesia, reducing technical complexity and animal stress while ensuring precise delivery into the pleural cavity. We demonstrate the effectiveness of this approach by achieving a 100% tumour engraftment rate following the injection of AE17 tumour cells. Additionally, this technique has been successfully used for asbestos fibre injection in mesothelioma models, highlighting its versatility. By providing a more accessible, standardised alternative to existing methods, this protocol improves the reliability of PM models and facilitates broader adoption by researchers, including those with limited experience in invasive procedures.

6 October 2025
Verified
Thesis
Closed access
Sophie Adriana Josepha Maria RoversSophie Adriana Josepha Maria Rovers
Sophie Adriana Josepha Maria Rovers
Pleural mesothelioma (PM) is a rare, aggressive malignancy of the lung lining, primarily caused by asbestos exposure. Its long latency period and late-stage diagnosis contribute to a poor prognosis, with five-year survival rates below 5%. While chemotherapy has been the historical standard, it offers limited benefit. Immune checkpoint inhibitors (ICIs) have recently shown promise by reactivating anti-tumour immunity, yet only a subset of patients responds, and resistance commonly develops. Concurrently, anti-angiogenic therapies targeting VEGF/VEGFR2 pathways have attracted interest, as abnormal tumour vasculature not only sustains growth but also restricts immune infiltration. This thesis explores whether co-targeting immune and vascular pathways, supplemented by physiological modulation through exercise, can improve therapeutic outcomes in mesothelioma. Chapter 2 establishes the rationale for combining anti-PD-L1 immunotherapy, anti-VEGFR2 anti-angiogenic therapy, and exercise, highlighting the interplay between angiogenesis, immune evasion, and vascular normalisation as a strategy to enhance immune activity. In a subcutaneous mesothelioma model (Chapter 3), dual blockade of PD-L1 and VEGFR2 significantly delayed tumour progression, extended survival, and induced vascular changes consistent with normalisation. CD4⁺ T cell depletion experiments revealed their central role in mediating therapeutic benefit and maintaining vascular integrity, underscoring the interdependence of immune and vascular mechanisms. To explore physiological modulation, Chapter 4 examined the addition of high-intensity interval training to combination therapy. Exercise preserved physical fitness and modestly influenced vascular structure but did not further enhance tumour control or survival in this model. These findings suggest that exercise-induced physiological changes may not always synergise with immunotherapy and should be tailored to tumour-specific contexts. Recognising the limitations of subcutaneous models, Chapters 5 and 6 describe the development of a minimally invasive intrapleural injection protocol to generate an orthotopic mesothelioma model and the re-evaluation of combination therapy within this context. In contrast to subcutaneous results, the therapy failed to improve survival or promote vascular normalisation, emphasising the critical influence of anatomical context on therapeutic efficacy. Together, this work demonstrates that effective mesothelioma treatment may require multifaceted approaches addressing immune, vascular, and physiological barriers. By integrating insights across diverse models, this dissertation provides a foundation for refining immune–vascular co-targeting and developing multimodal strategies to improve patient outcomes.